• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

TEMSIROLIMUS Drug Record

  • Summary
  • Interactions
  • Claims
  • TEMSIROLIMUS chembl:CHEMBL1201182 ApprovedAntineoplasticImmunotherapy

    Alternate Names:

    CCI-779
    TORISEL
    TEMSIROLIMUS
    CCI 779
    TORISEL®
    42-[3-HYDROXY-2-(HYDROXYMETHYL)-2-METHYLPROPANOATE]RAPAMYCIN
    drugbank:06287
    pubchem.compound:6918289
    rxcui:657797
    chembl:CHEMBL1201182
    chemidplus:162635-04-3

    Drug Info:

    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antineoplastic agent
    Pharmaceutical Developer Wyeth Pharmaceuticals
    Source Reported Drug Name(s) Temsirolimus
    Drug Class mTOR Inhibitor
    Notes rapalogue
    Drug Class Kinase Inhibitors
    FDA Approval Renal cell carcinoma
    Year of Approval 2007
    Drug Class antineoplastic agents, protein kinase inhibitors
    (11 More Sources)

    Publications:

    Myers et al., 2016, Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study., Gynecol. Oncol.
    Weigelt et al., 2013, PI3K pathway dependencies in endometrioid endometrial cancer cell lines., Clin. Cancer Res.
    Neshat et al., 2001, Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR., Proc. Natl. Acad. Sci. U.S.A.
    Patard et al., 2008, Targeted therapy in renal cell carcinoma., World J Urol
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Radulovic et al., 2007, Sunitinib, sorafenib and mTOR inhibitors in renal cancer., J BUON
    Janku et al., 2011, PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors., Mol. Cancer Ther.
    Liu et al., 2009, Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin., Cancer Res.
    Basho et al., 2017, Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab., JAMA Oncol
    Grünwald et al., 2015, TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO)., Ann. Oncol.
    Liu et al., 2011, The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway., J. Clin. Endocrinol. Metab.
    Janku et al., 2012, PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations., J. Clin. Oncol.
    Fleming et al., 2012, Phase II trial of temsirolimus in patients with metastatic breast cancer., Breast Cancer Res. Treat.
    Hayes et al., 2016, Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression., Cancer Cell
    Gandhi et al., 2014, Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors., J. Clin. Oncol.
    Thomas et al., 2006, Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer., Nat. Med.
    Villaruz et al., 2014, Temsirolimus therapy in a patient with lung adenocarcinoma harboring an FBXW7 mutation., Lung Cancer
    Wen et al., 2014, Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02., Neuro-oncology
    Mbatchi LC et al., 2017, Association of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer., Cancer Chemother Pharmacol
    Moulder et al., 2015, Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer., Ann. Oncol.
  • TEMSIROLIMUS   NF2

    Interaction Score: 1.65

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25878190


    Sources:
    CIViC

  • TEMSIROLIMUS   FBXW7

    Interaction Score: 1.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type lung adenocarcinoma
    Response Type sensitive
    Approval Status Clinical Study

    PMIDs:
    24360397


    Sources:
    JAX-CKB

  • TEMSIROLIMUS   VHL

    Interaction Score: 0.55

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16341243


    Sources:
    CIViC

  • TEMSIROLIMUS   CTNNB1

    Interaction Score: 0.48

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type endometrial cancer
    Response Type predicted – sensitive
    Approval Status Phase II

    PMIDs:
    27016228


    Sources:
    JAX-CKB

  • TEMSIROLIMUS   MTOR

    Interaction Score: 0.39

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Reported Cancer Type Lung
    Trial Name temsirolimus, CCI-779,Torisel

    PMIDs:
    18265991 11752352 17935273


    Sources:
    TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial TEND CancerCommons MyCancerGenomeClinicalTrial TTD OncoKB

  • TEMSIROLIMUS   PIK3CA

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type colorectal cancer
    Response Type sensitive
    Approval Status Clinical Study

    PMIDs:
    19706758 27893038 25527417 21289267 22271473 22245973 27016228 21216929


    Sources:
    ClearityFoundationBiomarkers JAX-CKB CIViC

  • TEMSIROLIMUS   FKBP1A

    Interaction Score: 0.32

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction FK506-binding protein 1A inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • TEMSIROLIMUS   PTEN

    Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type endometrial cancer
    Response Type no benefit
    Approval Status Phase II

    PMIDs:
    27016228 23674493 11504908


    Sources:
    ClearityFoundationBiomarkers JAX-CKB CIViC

  • TEMSIROLIMUS   KRAS

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy SCH772984 + Temsirolimus
    Indication/Tumor Type pancreatic ductal adenocarcinoma
    Response Type sensitive

    PMIDs:
    21216929 26725216 27016228


    Sources:
    ClearityFoundationBiomarkers JAX-CKB

  • TEMSIROLIMUS   BRAF

    Interaction Score: 0.13

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    combination therapy Bevacizumab + Temsirolimus + Doxil
    Indication/Tumor Type ovarian carcinoma
    Response Type sensitive

    PMIDs:
    21216929


    Sources:
    JAX-CKB MyCancerGenomeClinicalTrial

  • TEMSIROLIMUS   AKT1

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Phase II
    Response Type predicted – sensitive

    PMIDs:
    27016228


    Sources:
    JAX-CKB

  • TEMSIROLIMUS   NR1I2

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28676933


    Sources:
    PharmGKB

  • TEMSIROLIMUS   ERBB2

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Phase I
    Response Type predicted – sensitive

    PMIDs:
    24323026


    Sources:
    JAX-CKB

  • TEMSIROLIMUS   EGFR

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Response Type no benefit
    combination therapy Temsirolimus + Erlotinib
    Indication/Tumor Type malignant glioma

    PMIDs:
    24470557


    Sources:
    JAX-CKB

  • TEMSIROLIMUS   ABCB1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28676933


    Sources:
    PharmGKB

  • TEND: TEMSIROLIMUS

    • Version: 01-August-2011

    Alternate Names:
    TEMSIROLIMUS Primary Drug Name

    Drug Info:
    Drug Class antineoplastic agents, protein kinase inhibitors
    Year of Approval 2007

    Publications:

  • CancerCommons: TEMSIROLIMUS

    • Version: 25-July-2013

    Alternate Names:
    Temsirolimus PubChem Drug Name
    6918289 PubChem Drug ID
    Torisel Drug Trade Name

    Drug Info:
    Drug Class mTOR Inhibitor
    Source Reported Drug Name(s) Temsirolimus
    Pharmaceutical Developer Wyeth Pharmaceuticals

    Publications:

  • MyCancerGenome: TEMSIROLIMUS

    • Version: 20-Jun-2017

    Alternate Names:
    CCI-779 Development Name
    TEMSIROLIMUS Generic Name
    TORISEL Trade Name

    Drug Info:
    FDA Approval Renal cell carcinoma
    Drug Class Kinase Inhibitors
    Notes rapalogue

    Publications:

  • TdgClinicalTrial: TEMSIROLIMUS

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • PharmGKB: temsirolimus

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Mbatchi LC et al., 2017, Association of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer., Cancer Chemother Pharmacol

  • JAX-CKB: Temsirolimus

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Myers et al., 2016, Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study., Gynecol. Oncol.
    Janku et al., 2011, PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors., Mol. Cancer Ther.
    Wen et al., 2014, Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02., Neuro-oncology

  • CIViC: TEMSIROLIMUS

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Liu et al., 2009, Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin., Cancer Res.
    Thomas et al., 2006, Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer., Nat. Med.
    Moulder et al., 2015, Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer., Ann. Oncol.

  • TTD: Temsirolimus

    • Version: 2020.06.01

    Alternate Names:
    D0ES1Q TTD Drug ID

    Drug Info:

    Publications:

  • TALC: TEMSIROLIMUS

    • Version: 12-May-2016

    Alternate Names:
    TEMSIROLIMUS Primary Drug Name
    TEMSIROLIMUS Drug Generic Name
    TORISEL Drug Trade Name

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1201182

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1201182

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • MyCancerGenomeClinicalTrial: TEMSIROLIMUS

    • Version: 30-February-2014

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationBiomarkers: TEMSIROLIMUS

    • Version: 26-July-2013

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationClinicalTrial: TEMSIROLIMUS

    • Version: 15-June-2013

    Alternate Names:

    Drug Info:

    Publications:

  • OncoKB: Temsirolimus

    • Version: 23-July-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21